Loading...
•
Jun 30, 2022
ALX Oncology Q2 2022 Earnings Report
ALX Oncology's financial results for the second quarter of 2022 were reported, along with clinical development and operational highlights.
Key Takeaways
ALX Oncology reported a net loss of $32.9 million for the second quarter of 2022. The company's cash, cash equivalents, and investments totaled $324.2 million as of June 30, 2022, which is expected to fund operations through the fourth quarter of 2024. The FDA granted Fast Track designation to evorpacept for HNSCC and Orphan Drug Designation for AML.
FDA granted Fast Track designation to evorpacept for first-line treatment of HNSCC.
FDA granted Orphan Drug Designation to evorpacept for the treatment of patients with AML.
ASPEN-07, a Phase 1 trial of evorpacept for the treatment of patients with urothelial carcinoma, is anticipated to start in Q4 2022.
Patient enrollment continues for ASPEN-03 and ASPEN-04, Phase 2 studies for advanced HNSCC, with results expected by mid-2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...